Wall Street Legend Issues New NVDA Warning

Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.

Hazel Hunt Biography and Net Worth

Insider of Corcept Therapeutics

Dr. Hunt was named Corcept’s Chief Scientific Officer in 2020 serving, prior to that, as its Senior Vice President, Research. Dr. Hunt joined Corcept in 2011, bringing with her more than 23 years of experience in the pharmaceutical and biotechnology industries. From 2002 to 2011, Dr. Hunt was Director of Chemistry and Operations at Argenta, where she worked closely with Corcept and played an integral role in the discovery of Corcept’s portfolio of next-generation selective GR antagonists. From 1994 to 2002, she worked for Celltech, initially as a Group Leader in Medicinal Chemistry and ultimately as Section Leader, Project Chemistry. From 1992 to 1994, she served as a Research Fellow at The Centre for Drug Design and Development. Before that Dr. Hunt worked at Glaxo Group Research as a Senior Chemist in Medicinal Chemistry. Dr. Hunt received a first-class honors degree in chemistry from the Australian National University and a PhD in synthetic organic chemistry from the University of Southampton, UK. She also carried out postdoctoral work at Oxford University and the University of California at Irvine.

What is Hazel Hunt's net worth?: The estimated net worth of Hazel Hunt is at least $1.67 million as of August 14th, 2023. Dr. Hunt owns 73,146 shares of Corcept Therapeutics stock worth more than $1,667,729 as of April 28th. This net worth evaluation does not reflect any other assets that Dr. Hunt may own. Additionally, Dr. Hunt receives an annual salary of $895,160.00 as Insider at Corcept Therapeutics. Learn More about Hazel Hunt's net worth.
How old is Hazel Hunt?: Dr. Hunt is currently 64 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Hazel Hunt's age.
What is Hazel Hunt's salary?: As the Insider of Corcept Therapeutics Incorporated, Dr. Hunt earns $895,160.00 per year. There are 4 executives that earn more than Dr. Hunt. The highest earning executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who commands a salary of $2,430,000.00 per year. Learn More on Hazel Hunt's salary.
How do I contact Hazel Hunt?: The corporate mailing address for Dr. Hunt and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Hazel Hunt's contact information.
Has Hazel Hunt been buying or selling shares of Corcept Therapeutics?: Hazel Hunt has not been actively trading shares of Corcept Therapeutics over the course of the past ninety days. Most recently, Hazel Hunt sold 20,455 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $30.89, for a transaction totalling $631,854.95. Following the completion of the sale, the insider now directly owns 73,146 shares of the company's stock, valued at $2,259,479.94. Learn More on Hazel Hunt's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 300,108 shares worth more than $8,242,381.33. The most recent insider tranaction occured on April, 4th when insider Joseph Douglas Lyon sold 5,443 shares worth more than $141,518.00. Insiders at Corcept Therapeutics own 19.8% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 4/4/2024.

Hazel Hunt Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/14/2023	Sell	20,455	$30.89	$631,854.95	73,146

Hazel Hunt Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $22.80

$22.28

$23.22

50 Day Range

MA: $23.81

$21.66

$25.74

2 Week Range

Now: $22.80

$20.84

$34.28

Volume

820,551 shs

Average Volume

995,117 shs

Market Capitalization

$2.37 billion

P/E Ratio

24.00

Dividend Yield

N/A

Beta

0.48

Wall Street Legend Issues New NVDA Warning

From Chaikin Analytics | Ad

Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.

Click here for the stock details

Hazel Hunt Biography and Net Worth

What is Hazel Hunt's net worth?

How old is Hazel Hunt?

What is Hazel Hunt's salary?

How do I contact Hazel Hunt?

Has Hazel Hunt been buying or selling shares of Corcept Therapeutics?

Who are Corcept Therapeutics' active insiders?

Are insiders buying or selling shares of Corcept Therapeutics?